<DOC>
	<DOC>NCT00548691</DOC>
	<brief_summary>The Objective of this study is to study the safety of FCM in patients with anemia caused by chronic kidney failure</brief_summary>
	<brief_title>Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Anemia, Iron-Deficiency</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Male or Female 18 to 85 years of age NDDCKD Patients TSAT &lt;/= 25% Hgb &lt;/= 11.5 Ferritin &lt;/= 300 HDCKD Patients TSAT &lt;/= 30% Hgb &lt;/= 12 Ferritin &lt;/= 500 Previous participation in a FCM trial Known Hypersensitivity to FCM History of anemia other that anemia due to chronic renal failure Current history of GI bleeding Received IV Iron within the last 30 Days Anticipated need for surgery Malignancy history AST or ALT greater than normal Received an investigational drug within 30 days of screening Pregnant or sexually active females who are not willing to use an effective form of birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>